Volcano Corp. (NSDQ:VOLC) promoted David Sheehan to the role of chief operating officer, regulatory filings show.
Volcano Corp.
NuVasive swings to Q4, 2011 red | Earnings Roundup
NuVasive (NSDQ:NUVA) swung to red for the 4th quarter and full-year 2011, largely on the back of an $18.2 million writedown of intangible assets.
The San Diego-based spinal implant maker posted a loss of $10.0 million, or 24 cents per share, on sales of $150.2 million for the 3 months ended Dec. 31, 2012. That’s a top-line gain of 16.2% compared with Q4 2010, when NuVasive posted profits of $61.9 million, or $1.39 EPS.
Will Advanced BioHealing pay off for Shire with a buyout deal? | Wall Street Beat
Buyout chatter pushed shares of Shire plc (FTSE:SHP) up nearly 2% in London yesterday and added 1.4% on Wall Street.
Volcano beats The Street but guides low for 2012
Volcano Corp. (NSDQ:VOLC) blew away analysts’ expectations for the 4th quarter and 2011, but lost some love on Wall Street over its low guidance for 2012.
The San Diego-based company reported a 14% bump in sales to $92.7 million, compared to $81.2 million for the same period in 2010, and $29.4 million in profit, compared to a loss of $1.7 million during Q4 2010. That translates to 54 cents EPS – 14 cents EPS on an adjusted basis, nearly triple analysts’ expectations of 5 cents apiece.
St. Jude launches Asian FFR economics study
St. Jude Medical (NYSE:STJ) is launching a study to examine the economics of coronary interventions using fractional flow reserve in Japan, China, India, Korea, and Australia.
The analysis, based on the results of the Fame trial comparing FFR-guided procedures with those guided by angiography, plus statistics from country-specific percutaneous coronary intervention registries and other studies.
AngioDynamics details $372M Navilyst buyout details | Wall Street Beat
Financial projections from AngioDynamics (NSDQ:ANGO) about its $372 million deal to acquire Navilyst Medical show that it expects to reap some significant rewards from the merger over the short and long terms.
Goldman pans Wall Street’s med-tech estimates
Wall Street’s overall take on sales and earnings forecasts for medical device makers this year is too high, according to Goldman Sachs (NYSE:GS) analyst David Roman, who sees The Street’s 4th-quarter top-line estimates as split evenly among companies with upside and downside.
St. Jude’s Fame II FFR trial halted on positive results
St. Jude Medical (NYSE:STJ) said it’s halting its Fame II trial after an independent safety advisory board recommended the trial be stopped due to strong positive results.
JP Morgan 2012: A slew of med-tech companies preview earnings
A slew of medical device companies are providing a sneak preview of the upcoming earnings season at the JP Morgan Conference in San Francisco this week.
MassDevice is on site at the conference and will have updates coming throughout the week on one of the largest meetings of the medical technology investment community.
Bankers’ outlook grim for U.S. IPOs | Wall Street Beat
Bankers aren’t expecting much excitement in the U.S. market for initial public offerings this year, as China spends another year at the top.
About half of the 100 capital markets execs surveyed predict growth in IPOs this year, compared to 72% of those surveyed in advance of 2011, according to BDO USA, an accounting and consulting firm.
Only 16% of those surveyed expected any growth to be "significant," while 35% expect flat growth and 15% predicted that the market will continue to slide.
Volcano touts “excellent diagnostic efficiency” for drug-free ischemia detection system
Volcano Corp.’s (NSDQ:VOLC) instant wave-Free Ratio coronary lesion detector proved highly effective at diagnosing coronary lesions, according to the results of the company’s Advise trials.
The instant wave-Free Ratio (iFR) system, under investigational device exemption in the U.S., aims to provide a pharmaceutical-free alternative to the gold standard fractional flow reserve (FFR) method for assessing narrowed blood vessels.